Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models

In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system’s natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncoimmunology
Prif Awduron: Rothschilds, Adrienne, Tzeng, Alice, Mehta, Naveen K., Moynihan, Kelly D., Irvine, Darrell J., Wittrup, K. Dane
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2019
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492973/
https://ncbi.nlm.nih.gov/pubmed/31069130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1558678
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg